# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate ...
-SEC Filing
Maxim Group analyst Naz Rahman maintains Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy and lowers the price target from $15...
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(2.08) per share which beat the analyst consensus estimate of...
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...